Notice Number: NOT-AI-19-053
Key Dates
Release Date: March 28, 2019
Issued by
National Institute of Allergy and Infectious Diseases (NIAID)
Purpose
This Notice is to inform potential applicants that the NIAID is revising the award budget language in PAR-18-632, NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required).
Part 2. Full Text of Announcement
Section II. Award Information
Award Budget
Currently reads:
According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics. The current list of approved topics can be found at https://sbir.nih.gov/funding#omni-sbir. Applicants are strongly encouraged to contact NIH program officials prior to submitting any application in excess of the guidelines and early in the application planning process. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.
Revised to read:
The budget for this SBIR phase II clinical trial implementation solicitation cannot exceed $1 million per year (total costs) for up to 3 years. NIH has received a waiver from Small Business Administration, as authorized by statute, to exceed the hard cap of $225,000 (total project costs) for Phase I or $1,600,000 (total project costs) for Phase II for specific topics. The current list of approved topics and NIAID-specific budget caps can be found at https://sbir.nih.gov/funding#omni-sbir. Navigate to the “Program Descriptions and Research Topics” document. Applicants are strongly encouraged to contact NIAID program officials prior to submitting an application in excess of the aforementioned hard caps and early in the application planning process. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.
All other aspects of the FOA remain unchanged.
Inquiries
Please direct all inquiries to:
Natalia Kruchinin Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 301-496-8666
Email: [email protected]